Hyperbaric Oxygen Treatment for Long COVID: From Molecular Mechanism to Clinical Practice

Curr Med Sci. 2023 Dec;43(6):1061-1065. doi: 10.1007/s11596-023-2799-1. Epub 2023 Nov 4.

Abstract

Long COVID symptoms typically occur within 3 months of an initial COVID-19 infection, last for more than 2 months, and cannot be explained by other diagnoses. The most common symptoms include fatigue, dyspnea, coughing, and cognitive impairment. The mechanisms of long COVID are not fully understood, but several hypotheses have been put forth. These include coagulation and fibrosis pathway activation, inflammatory and autoimmune manifestations, persistent virus presence, and Epstein-Barr virus reactivation. Hyperbaric oxygen therapy (HBOT) is a therapeutic method in which a person inhales 100% oxygen under pressure greater than that of the atmosphere. HBOT has some therapeutic effects, including improvement of microcirculation, inhibition of cytokine release leading to a reduction in inflammatory responses, inhibition of autoimmune responses, and promotion of neurological repair. Several clinical trials have been carried out using HBOT to treat long COVID. The results suggest that HBOT helps to improve symptom severity, reduce symptom duration, and enhance patients' quality of life. It is believed that HBOT is an effective option for patients with long COVID, which is worth actively promoting.

Keywords: SARS-CoV-2; hyperbaric oxygen therapy; long COVID; post-COVID-19 condition.

MeSH terms

  • COVID-19* / therapy
  • Epstein-Barr Virus Infections*
  • Herpesvirus 4, Human
  • Humans
  • Hyperbaric Oxygenation* / methods
  • Oxygen
  • Post-Acute COVID-19 Syndrome
  • Quality of Life

Substances

  • Oxygen